AbbVie News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

20.06.14	WDH: Britischer Pharmakonzern Shire will sich nicht schlucken lassen (dpa-afx)
20.06.14	Shire Confirms Rejection Of AbbVie Proposal - Quick Facts (RTTNews)
20.06.14	Pharmakonzern Shire will sich nicht schlucken lassen (dpa-afx)
16.06.14	Biogen Idec, AbbVie Announce Positive Results From Phase 3 DECIDE Clinical Trial (RTTNews)
12.06.14	Moody's: New Cancer Drugs Create Big Opportunities in Pharmaceutical Industry (Moodys)
11.06.14	OraSure And AbbVie To Co-promote OraQuick HCV Rapid Test In U.S. - Quick Facts (RTTNews)
31.05.14	Seattle Genetics Reports Data From Collaborator ADC Programs - Quick Facts (RTTNews)
30.05.14	AbbVie To Continue Study Of ABT-414 For Glioblastoma Multiforme Brain Cancer (RTTNews)
23.05.14	EDAP Confirms FDA Panel Date, ISIS Reports Data, RedHill Touches New Peak (RTTNews)
19.05.14	Bristol-Myers, AbbVie Say Elotuzumab Gets FDA Breakthrough Therapy Designation (RTTNews)
17.05.14	Abbott Laboratories -- Moody's: Abbott's acquisition of CFR Pharmaceuticals is credit positive; ratings unaffected (Moodys)
25.04.14	AbbVie Q1 Results Beat Estimates On Strong Humira Sales, Backs FY View - Update (RTTNews)
25.04.14	AbbVie Q1 Profit Rises, Results Top Estimates; Backs 2014 Outlook - Quick Facts (RTTNews)
22.04.14	AbbVie Submits NDA To FDA For Investigational, All-Oral, Interferon-Free Therapy (RTTNews)
16.04.14	DVAX Moves On, GSK Gets FDA Nod, HART-Warming, ZGNX Gains On Favorable Ruling (RTTNews)
15.04.14	AbbVie Begins Phase III Trial Of Veliparib For NSCLC Patients (RTTNews)
12.04.14	AbbVie To Present TURQUOISE-II Study Results At ILC (RTTNews)
11.04.14	AbbVie To Present Results From SAPPHIRE-I Study At International Liver Congress (RTTNews)
20.03.14	AbbVie Initiates Phase 3 Trial For HUMIRA (RTTNews)
04.03.14	AbbVie Inc. -- Moody's revises AbbVie's outlook to positive (Moodys)
25.02.14	Moody's: AbbVie, Amgen and Roche most exposed to biosimilar drugs market (Moodys)
01.02.14	FDA Investigates Heart Risks Of Testosterone Products (RTTNews)
31.01.14	AbbVie Q4 Profit Down 27%, But Meets View; Completes Hepatitis C Drug Trials (RTTNews)
31.01.14	AbbVie Q4 Profit Down; Sees 2014 Adj. EPS Below View - Quick Facts (RTTNews)
15.01.14	AbbVie Initiates Pivotal Phase 3 Study Of Veliparib - Quick Facts (RTTNews)
10.12.13	Enanta Pharmaceuticals Announces Results From SAPPHIRE-II Study - Quick Facts (RTTNews)
28.11.13	Health Canada Approves HUMIRA For Ulcerative Colitis - Quick Facts (RTTNews)
25.10.13	AbbVie Q3 Profit Beats Estimates - Quick Facts (RTTNews)
18.10.13	Financial Results, Quarterly Earnings Schedules, Marketing Authorizations, Completed Acquisitions, and New Drug Applications - Research Report on Johnson & Johnson, AbbVie, GSK, AstraZeneca, and Keryx (PR Newswire)
09.10.13	Data From Largest Global RA Patient Survey Reveals Patients Value A Disease Management Plan (PR Newswire)
04.10.13	Under AAAResearchReports.com Microscope: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. (PR Newswire)
03.10.13	AbbVie Reports Results From HUMIRA Phase II Study - Quick Facts (RTTNews)
03.10.13	AbbVie Presents Phase II Data Evaluating the Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease (PR Newswire)
01.10.13	AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting (PR Newswire)
01.10.13	AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting (PR Newswire)
30.09.13	Drug Approvals, Trial Results, and Collaboration- Research Report on Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly, AbbVie, and GSK (PR Newswire)
25.09.13	Dividends and Recognitions Affirming Strong Returns to Shareholders- Research Report on Merck, AbbVie, HealthSouth, Quintiles, and Ensign (PR Newswire)
24.09.13	AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies (PR Newswire)
24.09.13	AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies (PR Newswire)
24.09.13	Stock Movements, Quarterly Dividends and Product Recall News - Research Report on Pfizer, Johnson & Johnson, Bristol-Myers, Merck, and Abbvie (PR Newswire)
23.09.13	AbbVie Signs License Deal For Inflammatory Diseases Drug Candidate With Ablynx (RTTNews)
23.09.13	Ablynx, AbbVie Sign Global License Agreement For Anti-IL-6R Nanobody, ALX-0061 (RTTNews)
23.09.13	Ablynx And AbbVie Sign Global License Agreement For anti-IL-6R Nanobody, ALX-0061, To Treat Inflammatory Diseases (PR Newswire)
23.09.13	Ablynx And AbbVie Sign Global License Agreement For anti-IL-6R Nanobody, ALX-0061, To Treat Inflammatory Diseases (PR Newswire)
19.09.13	AbbVie Declares Quarterly Dividend (PR Newswire)
02.09.13	Acquisitions, Topline Results, New Board Members, Events, and Product Milestones - Research Report on Johnson & Johnson, Sanofi, Lilly, AbbVie, and Novartis (PR Newswire)
29.08.13	Early Briefing and Review: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. (PR Newswire)
27.08.13	AbbVie to Present at Morgan Stanley Global Healthcare Conference (PR Newswire)
19.08.13	Vote to Help Award a $21,000 AbbVie CF Scholarship to Two Inspirational Students with Cystic Fibrosis Pursuing their Goals of Higher Education (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester

11.11.24

Börse New York in Grün: S&P 500 zum Handelsende freundlich

11.11.24

Optimismus in New York: S&P 500 am Nachmittag mit Kursplus

11.11.24

NYSE-Handel: S&P 500 mittags freundlich

11.11.24

Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

02.07.24

Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge

02.07.24

Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten